---
schema_version: "secwatch.filing_event.v1"
accession: "0001494650-24-000042"
form_type: "8-K"
ticker: null
cik: "0001494650"
company_name: "OptiNose, Inc."
filed_at: "2024-04-25T23:59:59+00:00"
generated_at: "2026-06-03T07:53:36.301071+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Optinose reports Q1 XHANCE revenue $14.9M (+26% YoY); sees peak >$300M

## Summary
- Q1 2024 XHANCE net revenue $14.9M, up ~26% vs Q1 2023.
- FDA approved XHANCE as first drug treatment for chronic sinusitis without nasal polyps.
- Expects peak XHANCE net revenue >$300M; positive GAAP ops income by FY2025.
- Leveraging 75 sales territories to target 3M patients; limited incremental spend.
- Plans to use specialty pharmacy hub to improve prescription fill and reimbursement.

## SEC filing metadata
- accession: 0001494650-24-000042
- form_type: 8-K
- cik: 0001494650
- company_name: OptiNose, Inc.
- filed_at: 2024-04-25T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1494650/000149465024000042/0001494650-24-000042-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1494650/000149465024000042/optn-20240425.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001494650-24-000042
- JSON: https://secwatch.observer/filing/0001494650-24-000042.json
- Plain text: https://secwatch.observer/filing/0001494650-24-000042.txt

## Key facts
- Earnings Releases
  OptiNose, Inc. reported the three months ended March 31, 2024 results: revenue $14.9 million. Guidance initiated.
  - Period: the three months ended March 31, 2024
  - Revenue: $14.9 million
  - Guidance: initiated
  - Result: preliminary results
  source text: the Company announced preliminary XHANCE net product revenue of $14.9 million for the three months ended March 31, 2024
  evidence_url: https://www.sec.gov/Archives/edgar/data/1494650/000149465024000042/0001494650-24-000042-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.